Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation

Detalhes bibliográficos
Autor(a) principal: Barbosa,S.C.M.
Data de Publicação: 2019
Outros Autores: Pereira,V.B.M., Wong,D.V.T., Santana,A.P.M., Lucetti,L.T., Carvalho,L.L., Barbosa,C.R.N., Callado,R.B., Silva,C.A.A., Lopes,C.D.H., Brito,G.A.C., Alencar,N.M.N., Lima-Júnior,R.C.P.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Medical and Biological Research
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2019000300601
Resumo: Oral mucositis (OM) is a common and dose-limiting side effect of cancer treatment, including 5-fluorouracil (5-FU) and radiotherapy. The efficacy of the therapeutic measures to prevent OM is limited and disease prevention is not fully observable. Amifostine is a cytoprotective agent with a described anti-inflammatory potential. It is clinically used to reduce radiotherapy and chemotherapy-associated xerostomia. This study investigated the protective effect of amifostine on an experimental model of OM. Hamsters were divided into six groups: saline control group (5 mL/kg), mechanical trauma (scratches) of the right cheek pouch; 5-FU (60 and 40 mg/kg, ip, respectively, administered on days 1 and 2); amifostine (12.5, 25, or 50 mg/kg) + 5-FU + scratches. Salivation rate was assessed and the animals were euthanized on day 10 for the analysis of macroscopic and microscopic injury by scores. Tissue samples were harvested for the measurement of neutrophil infiltration and detection of inflammatory markers by ELISA and immunohistochemistry. 5-FU induced pronounced hyposalivation, which was prevented by amifostine (P<0.05). In addition, 5-FU injection caused pronounced tissue injury accompanied by increased neutrophil accumulation, tumor necrosis factor-alpha (TNF-α), and interleukin-1 beta (IL-1β) tissue levels, and positive immunostaining for TNF-α, IL-1β, and inducible nitric oxide synthase (iNOS). Interestingly, amifostine prevented the inflammatory reaction and consequently improved macroscopic and microscopic damage (P<0.05 vs 5-FU group). Amifostine reduced inflammation and protected against 5-FU-associated oral mucositis and hyposalivation.
id ABDC-1_37f2be05f0c3751d436839352271c1d1
oai_identifier_str oai:scielo:S0100-879X2019000300601
network_acronym_str ABDC-1
network_name_str Brazilian Journal of Medical and Biological Research
repository_id_str
spelling Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivationCancer chemotherapy toxicityOral mucositis5-FluorouracilAmifostineCytokinesOral mucositis (OM) is a common and dose-limiting side effect of cancer treatment, including 5-fluorouracil (5-FU) and radiotherapy. The efficacy of the therapeutic measures to prevent OM is limited and disease prevention is not fully observable. Amifostine is a cytoprotective agent with a described anti-inflammatory potential. It is clinically used to reduce radiotherapy and chemotherapy-associated xerostomia. This study investigated the protective effect of amifostine on an experimental model of OM. Hamsters were divided into six groups: saline control group (5 mL/kg), mechanical trauma (scratches) of the right cheek pouch; 5-FU (60 and 40 mg/kg, ip, respectively, administered on days 1 and 2); amifostine (12.5, 25, or 50 mg/kg) + 5-FU + scratches. Salivation rate was assessed and the animals were euthanized on day 10 for the analysis of macroscopic and microscopic injury by scores. Tissue samples were harvested for the measurement of neutrophil infiltration and detection of inflammatory markers by ELISA and immunohistochemistry. 5-FU induced pronounced hyposalivation, which was prevented by amifostine (P<0.05). In addition, 5-FU injection caused pronounced tissue injury accompanied by increased neutrophil accumulation, tumor necrosis factor-alpha (TNF-α), and interleukin-1 beta (IL-1β) tissue levels, and positive immunostaining for TNF-α, IL-1β, and inducible nitric oxide synthase (iNOS). Interestingly, amifostine prevented the inflammatory reaction and consequently improved macroscopic and microscopic damage (P<0.05 vs 5-FU group). Amifostine reduced inflammation and protected against 5-FU-associated oral mucositis and hyposalivation.Associação Brasileira de Divulgação Científica2019-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2019000300601Brazilian Journal of Medical and Biological Research v.52 n.3 2019reponame:Brazilian Journal of Medical and Biological Researchinstname:Associação Brasileira de Divulgação Científica (ABDC)instacron:ABDC10.1590/1414-431x20188251info:eu-repo/semantics/openAccessBarbosa,S.C.M.Pereira,V.B.M.Wong,D.V.T.Santana,A.P.M.Lucetti,L.T.Carvalho,L.L.Barbosa,C.R.N.Callado,R.B.Silva,C.A.A.Lopes,C.D.H.Brito,G.A.C.Alencar,N.M.N.Lima-Júnior,R.C.P.eng2019-03-18T00:00:00Zoai:scielo:S0100-879X2019000300601Revistahttps://www.bjournal.org/https://old.scielo.br/oai/scielo-oai.phpbjournal@terra.com.br||bjournal@terra.com.br1414-431X0100-879Xopendoar:2019-03-18T00:00Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC)false
dc.title.none.fl_str_mv Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation
title Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation
spellingShingle Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation
Barbosa,S.C.M.
Cancer chemotherapy toxicity
Oral mucositis
5-Fluorouracil
Amifostine
Cytokines
title_short Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation
title_full Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation
title_fullStr Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation
title_full_unstemmed Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation
title_sort Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation
author Barbosa,S.C.M.
author_facet Barbosa,S.C.M.
Pereira,V.B.M.
Wong,D.V.T.
Santana,A.P.M.
Lucetti,L.T.
Carvalho,L.L.
Barbosa,C.R.N.
Callado,R.B.
Silva,C.A.A.
Lopes,C.D.H.
Brito,G.A.C.
Alencar,N.M.N.
Lima-Júnior,R.C.P.
author_role author
author2 Pereira,V.B.M.
Wong,D.V.T.
Santana,A.P.M.
Lucetti,L.T.
Carvalho,L.L.
Barbosa,C.R.N.
Callado,R.B.
Silva,C.A.A.
Lopes,C.D.H.
Brito,G.A.C.
Alencar,N.M.N.
Lima-Júnior,R.C.P.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Barbosa,S.C.M.
Pereira,V.B.M.
Wong,D.V.T.
Santana,A.P.M.
Lucetti,L.T.
Carvalho,L.L.
Barbosa,C.R.N.
Callado,R.B.
Silva,C.A.A.
Lopes,C.D.H.
Brito,G.A.C.
Alencar,N.M.N.
Lima-Júnior,R.C.P.
dc.subject.por.fl_str_mv Cancer chemotherapy toxicity
Oral mucositis
5-Fluorouracil
Amifostine
Cytokines
topic Cancer chemotherapy toxicity
Oral mucositis
5-Fluorouracil
Amifostine
Cytokines
description Oral mucositis (OM) is a common and dose-limiting side effect of cancer treatment, including 5-fluorouracil (5-FU) and radiotherapy. The efficacy of the therapeutic measures to prevent OM is limited and disease prevention is not fully observable. Amifostine is a cytoprotective agent with a described anti-inflammatory potential. It is clinically used to reduce radiotherapy and chemotherapy-associated xerostomia. This study investigated the protective effect of amifostine on an experimental model of OM. Hamsters were divided into six groups: saline control group (5 mL/kg), mechanical trauma (scratches) of the right cheek pouch; 5-FU (60 and 40 mg/kg, ip, respectively, administered on days 1 and 2); amifostine (12.5, 25, or 50 mg/kg) + 5-FU + scratches. Salivation rate was assessed and the animals were euthanized on day 10 for the analysis of macroscopic and microscopic injury by scores. Tissue samples were harvested for the measurement of neutrophil infiltration and detection of inflammatory markers by ELISA and immunohistochemistry. 5-FU induced pronounced hyposalivation, which was prevented by amifostine (P<0.05). In addition, 5-FU injection caused pronounced tissue injury accompanied by increased neutrophil accumulation, tumor necrosis factor-alpha (TNF-α), and interleukin-1 beta (IL-1β) tissue levels, and positive immunostaining for TNF-α, IL-1β, and inducible nitric oxide synthase (iNOS). Interestingly, amifostine prevented the inflammatory reaction and consequently improved macroscopic and microscopic damage (P<0.05 vs 5-FU group). Amifostine reduced inflammation and protected against 5-FU-associated oral mucositis and hyposalivation.
publishDate 2019
dc.date.none.fl_str_mv 2019-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2019000300601
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2019000300601
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/1414-431x20188251
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Brasileira de Divulgação Científica
publisher.none.fl_str_mv Associação Brasileira de Divulgação Científica
dc.source.none.fl_str_mv Brazilian Journal of Medical and Biological Research v.52 n.3 2019
reponame:Brazilian Journal of Medical and Biological Research
instname:Associação Brasileira de Divulgação Científica (ABDC)
instacron:ABDC
instname_str Associação Brasileira de Divulgação Científica (ABDC)
instacron_str ABDC
institution ABDC
reponame_str Brazilian Journal of Medical and Biological Research
collection Brazilian Journal of Medical and Biological Research
repository.name.fl_str_mv Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC)
repository.mail.fl_str_mv bjournal@terra.com.br||bjournal@terra.com.br
_version_ 1754302946852470784